Isrg.Ta
ISRG.TA operates in the Leisure & Recreation industry, providing services related to passenger airlines and leisure activities, generating revenue primarily through service fees and ticket sales.
Business. Intuitive Surgical Inc (ISRG.O) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates primarily through a product-sale revenue model within the Advanced Medical Equipment & Technology industry. Headquartered in the United States, the company is listed on the NASDAQ stock exchange. Specific operating segments and geographic revenue breakdowns are not disclosed in the available data.
Analyst recommendations
35 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressMarkwayne Mullin — Intuitive Surgical, Inc. - Common Stock2025-12-29 · Purchase · $15,001 - $50,000
- CongressJosh Gottheimer — Intuitive Surgical, Inc. - Common2025-09-03 · Democrat · NJ · Sale · $1,001 - $15,000
- CongressLisa McClain — Intuitive Surgical, Inc. - Common2025-07-16 · Republican · MI · Sale · $1,001 - $15,000
- CongressLisa McClain — Intuitive Surgical, Inc. - Common2025-07-10 · Republican · MI · Purchase · $1,001 - $15,000
- CongressLisa McClain — Intuitive Surgical, Inc. - Common2025-06-09 · Republican · MI · Sale · $1,001 - $15,000
- CongressJosh Gottheimer — Intuitive Surgical, Inc. - Common2025-04-09 · Democrat · NJ · Sale · $1,001 - $15,000
Pre-earnings brief
Intuitive Surgical Inc (ISRG.O) has experienced significant shifts in its institutional ownership structure, marked by major holder changes detected in late June and early July 2026. Specifically, investor ID 931 drastically reduced its position, cutting shares from 328,884 to just 535, a move that slashed its portfolio weight from approximately 7.15% to a negligible 0.0001%. This substantial divestment represents a major severity signal in the company's shareholder base, indicating a potential loss of confidence or a strategic reallocation by a key stakeholder. Concurrently, investor ID 587 exhibited volatile trading activity during the same period, with multiple detected changes involving swings between 6,105 shares and 160,803 shares. These fluctuations, detected between June 25 and June 27, 2026, suggest active repositioning or data reconciliation events within this holder's account. The final recorded position for this investor settled at 6,105 shares, valued at approximately $2.8 million, representing a weight of roughly 0.16% in their portfolio. Despite these notable movements in the shareholder registry, the broader market sentiment and news flow for Intuitive Surgical have remained quiet. Cross-source signal analysis shows zero dispatches and null sentiment readings for every day from June 23 through July 13, 2026. This absence of public news or analyst commentary contrasts with the private, major-severity changes occurring within the institutional holder data, suggesting that the recent ownership shifts have not yet triggered a broader market narrative or public reaction. The company's fundamental profile remains anchored by its existing corporate structure, which includes two officers, seven analysts covering the stock, and membership in two major indices. With 38 top holders currently on record, the recent exits and adjustments by specific investors like ID 931 and ID 587 highlight the dynamic nature of ISRG's institutional base. However, without accompanying changes in analyst estimates, financials, or ESG ratings, the immediate material impact of these holder changes on the company's valuation or operational outlook remains undefined in the current data set.
Signals & dispatch
Composite-score breakdown
Synthesis
Intuitive Surgical Inc (ISRG.O) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates primarily through a product-sale revenue model within the Advanced Medical Equipment & Technology industry. Headquartered in the United States, the company is listed on the NASDAQ stock exchange. Specific operating segments and geographic revenue breakdowns are not disclosed in the available data.
ISRG.TA has a high price-to-book ratio of 353.36, indicating that the market values the company significantly above its book value. The company's liquidity position is weak, as evidenced by a current ratio of 0.47, suggesting that it may struggle to meet short-term obligations with its current assets. Additionally, the company has a negative net cash position after subtracting total debt, which raises concerns about its short-term financial stability.
In terms of profitability, ISRG.TA has a return on equity (ROE) of 12.36%, which is relatively low compared to industry standards. The company's return on assets (ROA) is also low at 2.83%, indicating that it is not efficiently using its assets to generate profits. The operating margin is 3.75%, which is below the industry median, suggesting that the company is underperforming in terms of operational efficiency.
ISRG.TA's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to regional economic downturns and regulatory changes. The company's revenue concentration in a single segment also limits its ability to adapt to market shifts.
The company's growth trajectory is uncertain, with no significant revenue growth reported in the latest financial period. The free cash flow is negative at -17.74 million, indicating that the company is not generating enough cash to fund its operations and capital expenditures. The capital expenditure of -72.33 million suggests that the company is investing heavily in its operations, but the negative free cash flow raises concerns about the sustainability of these investments.
The risk assessment for ISRG.TA indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 1.23 suggests that it is moderately leveraged, but the negative net cash position after subtracting total debt is a red flag. The company has not made any recent adjustments to its valuation, and there are no indications of near-term dilution pressure.
Recent events and filings for ISRG.TA do not indicate any significant changes in the company's operations or financial strategy. The company has not issued any new shares or made any major acquisitions in the latest reporting period. The absence of recent events suggests a stable but stagnant business environment for the company.
Intuitive Surgical Inc (ISRG.O) has experienced significant shifts in its institutional ownership structure, marked by major holder changes detected in late June and early July 2026. Specifically, investor ID 931 drastically reduced its position, cutting shares from 328,884 to just 535, a move that slashed its portfolio weight from approximately 7.15% to a negligible 0.0001%. This substantial divestment represents a major severity signal in the company's shareholder base, indicating a potential loss of confidence or a strategic reallocation by a key stakeholder. Concurrently, investor ID 587 exhibited volatile trading activity during the same period, with multiple detected changes involving swings between 6,105 shares and 160,803 shares. These fluctuations, detected between June 25 and June 27, 2026, suggest active repositioning or data reconciliation events within this holder's account. The final recorded position for this investor settled at 6,105 shares, valued at approximately $2.8 million, representing a weight of roughly 0.16% in their portfolio. Despite these notable movements in the shareholder registry, the broader market sentiment and news flow for Intuitive Surgical have remained quiet. Cross-source signal analysis shows zero dispatches and null sentiment readings for every day from June 23 through July 13, 2026. This absence of public news or analyst commentary contrasts with the private, major-severity changes occurring within the institutional holder data, suggesting that the recent ownership shifts have not yet triggered a broader market narrative or public reaction. The company's fundamental profile remains anchored by its existing corporate structure, which includes two officers, seven analysts covering the stock, and membership in two major indices. With 38 top holders currently on record, the recent exits and adjustments by specific investors like ID 931 and ID 587 highlight the dynamic nature of ISRG's institutional base. However, without accompanying changes in analyst estimates, financials, or ESG ratings, the immediate material impact of these holder changes on the company's valuation or operational outlook remains undefined in the current data set.
- ISRG.TA has a high price-to-book ratio, indicating that the market values the company significantly above its book value.
- The company's liquidity position is weak, with a current ratio of 0.47 and a negative net cash position after subtracting total debt.
- ISRG.TA's profitability metrics, including ROE and ROA, are below industry standards, suggesting inefficiencies in asset utilization and profit generation.
- The company's revenue is concentrated in a single business segment, increasing its exposure to regional economic downturns and regulatory changes.
- ISRG.TA's growth trajectory is uncertain, with no significant revenue growth and a negative free cash flow, raising concerns about the sustainability of its capital expenditures.
- **margin_outlook_rationale**: The company's operating margin is below the industry median, indicating potential inefficiencies in cost management and pricing strategies.
- **rd_outlook_rationale**: There is no specific information provided about the company's research and development activities or their expected impact on future performance.
Bull / Bear case
Generated · model-assistedRevenue is projected to grow 20.5% year-over-year to $10.06 billion in fiscal 2026, demonstrating strong top-line expansion.
Free cash flow is expected to surge 74.4% to $3.0 billion in fiscal 2026, highlighting exceptional cash generation capabilities.
Operating margins of 28.2% rank in the top quartile of the Advanced Medical Equipment cohort, indicating superior profitability.
Analysts project 65.4% upside to a mean price target of $581.15, reflecting strong consensus confidence in future performance.
The company maintains zero long-term debt and a low leverage band, providing significant financial flexibility and stability.
Return on equity of 3.58% is significantly lower than peers like GE Healthcare, suggesting less efficient capital utilization.
Capex to revenue ratio of -27.43% places the company in the bottom quartile of its peer cohort.
In focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director, Chief Executive Officer (CEO) · Restricted Stock Units - 6-12-23 → Common StockDisposed 1 358exercise · 2026-06-10
- SVP & GM da Vinci Platforms & · Non-Qualified Stock Option (right to buy) → Common StockDisposed 5 625 @ $77,00exercise · 2026-06-01
- Director · Restricted Stock Units → Common StockDisposed 531exercise · 2026-04-30
- Director · Restricted Stock Units - 4-30-2026 → Common StockAcquired 643grant · 2026-04-30
- Director · Restricted Stock Units → Common StockDisposed 750exercise · 2026-04-30
- Director · Restricted Stock Units - 4-30-2026 → Common StockAcquired 554grant · 2026-04-30
- Director · Restricted Stock Units → Common StockDisposed 531exercise · 2026-04-30
- Director · Restricted Stock Units - 4-30-2026 → Common StockAcquired 554grant · 2026-04-30
- Director · Restricted Stock Units → Common StockDisposed 531exercise · 2026-04-30
- Director · Restricted Stock Units - 4-30-2026 → Common StockAcquired 554grant · 2026-04-30
- Director · Restricted Stock Units → Common StockDisposed 531exercise · 2026-04-30
- Director · Restricted Stock Units - 4-30-2026 → Common StockAcquired 554grant · 2026-04-30
- Director · Restricted Stock Units → Common StockDisposed 531exercise · 2026-04-30
- Director · Restricted Stock Units - 4-30-2026 → Common StockAcquired 554grant · 2026-04-30
- Director · Restricted Stock Units → Common StockDisposed 531exercise · 2026-04-30
- Director · Restricted Stock Units - 4-30-2026 → Common StockAcquired 554grant · 2026-04-30
- Director · Restricted Stock Units → Common StockDisposed 531exercise · 2026-04-30
- Director · Restricted Stock Units - 4-30-2026 → Common StockAcquired 554grant · 2026-04-30
- Director · Restricted Stock Units → Common StockDisposed 531exercise · 2026-04-30
- Director · Restricted Stock Units - 4-30-2026 → Common StockAcquired 554grant · 2026-04-30
- EVP & Chief Medical Officer · Non-Qualified Stock Option (right to buy) → Common StockDisposed 105 @ $229,39exercise · 2026-03-10
- EVP & Chief Medical Officer · Non-Qualified Stock Option (right to buy) → Common StockDisposed 125 @ $208,90exercise · 2026-03-02
- VP Corporate Controller · Restricted Stock Units → Common StockDisposed 468exercise · 2026-02-28
- SVP & GM da Vinci Platforms & · Performance Stock Units - 2-28-2023 → Common StockDisposed 8 378exercise · 2026-02-28
- SVP & GM da Vinci Platforms & · Restricted Stock Units - 2-28-2022 → Common StockDisposed 626exercise · 2026-02-28
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- ISRG.TA Market data — financials · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,96 %$1 402M
- Investment Managers · as of 2026-03-310,70 %$2 159M
- Investment Managers · as of 2026-03-310,67 %$6M
- Investment Managers · as of 2026-03-310,60 %$1 776M
- Investment Managers · as of 2026-03-310,53 %$971M
- Investment Managers · as of 2024-12-310,51 %$1 793M
- Investment Managers · as of 2026-03-310,51 %$3 710M
- Investment Managers · as of 2026-03-310,50 %$972M
- Investment Managers · as of 2026-03-310,38 %$599M
- Institutional Investor · as of 2026-03-310,38 %$757M
- Institutional Investor · as of 2022-09-300,37 %$0M
- Investment Managers · as of 2026-03-310,34 %$1 825M
- Investment Managers · as of 2024-06-300,30 %$13 400M
- Institutional Investor · as of 2026-03-310,30 %$1 637M
- Investment Managers · as of 2025-12-310,28 %$19 037M
- Investment Managers · as of 2026-03-310,26 %$1 078M
- Funds · as of 2026-03-310,26 %$1 723M
- Investment Managers · as of 2026-03-310,25 %$7 305M
- Investment Managers · as of 2026-03-310,24 %$3 888M
- Investment Managers · as of 2026-03-310,21 %$1 615M
- Investment Managers · as of 2026-03-310,18 %$1 210M
- Investment Managers · as of 2026-03-310,17 %$2 793M
- Investment Managers · as of 2026-03-310,15 %$284M
- Investment Managers · as of 2026-03-310,15 %$1 130M
- Institutional Investor · as of 2026-03-310,14 %$604M
- Investment Managers · as of 2026-03-310,13 %$755M
- Institutional Investor · as of 2026-03-310,13 %$2 525M
- Brokerage Firms · as of 2026-03-310,10 %$483M
- Brokerage Firms · as of 2026-03-310,09 %$285M
- Institutional Investor · as of 2026-03-310,07 %$149M
- Investment Managers · as of 2026-03-310,06 %$297M
- Investment Managers · as of 2026-03-310,05 %$77M
- Investment Managers · as of 2026-03-310,05 %$118M
- Investment Managers · as of 2026-03-310,05 %$202M
- Investment Managers · as of 2026-03-310,04 %$74M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- David J. RosaPresident, Director
- David J. RosaPresident, Director
Insider activity
- EVP & Chief Mfg and Supply Cha · Common StockSold 25 @ $414,13$10K · 2026-06-12
- EVP & Chief Mfg and Supply Cha · Common StockSold 23 @ $412,16$9K · 2026-06-11
- EVP & Chief Legal and Complian · Common StockSold 400 @ $424,14$170K · 2026-06-10
- Director, Chief Executive Officer (CEO) · Common StockOther 1 358 · 2026-06-10
- Director, Chief Executive Officer (CEO) · Common StockOther 674 @ $426,61$288K · 2026-06-10
- EVP & Chief Mfg and Supply Cha · Common StockSold 23 @ $424,14$10K · 2026-06-10
- EVP & Chief Mfg and Supply Cha · Common StockSold 23 @ $421,13$10K · 2026-06-09
- EVP & Chief Mfg and Supply Cha · Common StockSold 23 @ $420,12$10K · 2026-06-08
- SVP & GM da Vinci Platforms & · Common StockSold 5 625 @ $420,55$2,4M · 2026-06-01
- SVP & GM da Vinci Platforms & · Common StockOther 5 625 @ $77,00$433K · 2026-06-01
- EVP & Chief Mfg and Supply Cha · Common StockSold 18 @ $439,80$8K · 2026-05-22
- EVP & Chief Mfg and Supply Cha · Common StockSold 18 @ $446,04$8K · 2026-05-21
- EVP & Chief Mfg and Supply Cha · Common StockSold 18 @ $440,38$8K · 2026-05-20
- EVP & Chief Mfg and Supply Cha · Common StockSold 18 @ $440,70$8K · 2026-05-19
- EVP & Chief Mfg and Supply Cha · Common StockSold 18 @ $422,47$8K · 2026-05-18
- EVP & Chief Legal and Complian · Common StockSold 400 @ $446,95$179K · 2026-05-11
- Director · Common StockOther 531 · 2026-04-30
- Director · Common StockOther 750 · 2026-04-30
- Director · Common StockOther 531 · 2026-04-30
- Director · Common StockOther 531 · 2026-04-30
- Director · Common StockOther 531 · 2026-04-30
- Director · Common StockOther 531 · 2026-04-30
- Director · Common StockOther 531 · 2026-04-30
- Director · Common StockOther 531 · 2026-04-30
- Director · Common StockOther 531 · 2026-04-30
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Current ratio (FY 2025-12-31): 4.87xDerived (calculated)
- Return on assets (FY 2025-12-31): 14.0%Derived (calculated)
- Gross margin (FY 2025-12-31): 66.0%Derived (calculated)
- Return on equity (FY 2025-12-31): 16.0%Derived (calculated)
- Net margin (FY 2025-12-31): 28.4%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 8.5%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 9.2%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 13.7%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 20.5%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 14.5%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 25.4%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 25.5%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 23.0%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 17.9%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 22.6%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 22.3%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 25.9%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 66.1%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.14xDerived (calculated)
- Operating cash flow (annual): USD 3.03BSEC XBRL filing
- R&D expense (annual): USD 1.31BSEC XBRL filing
- Gross profit (annual): USD 6.64BSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 8SEC XBRL filing
- Total assets (annual): USD 20.46BSEC XBRL filing